Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 838 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: Cancer of Head and Neck, Neoplasms, Head and Neck
Interventions: Erlotinib, Green Tea Polyphenon E; Drug · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Metastatic Colorectal Cancer
Interventions: MEN1611, Cetuximab; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Phoenix, Arizona • Anaheim, California • Tacoma, Washington

Conditions: Breast Cancer
Interventions: GDC-4198, Giredestrant, Abemaciclib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Huntsville, Alabama • Tucson, Arizona • Duarte, California + 29 more

Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Interventions: Neratinib, Fulvestrant, Trastuzumab, Paclitaxel; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more

Conditions: Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: EGFR Antisense DNA; Biological
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Colorectal Cancer, Neoplasm Metastasis
Interventions: Cetuximab, Oxaliplatin, Capecitabine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: ASP-1929 Photoimmunotherapy, Physician's Choice SOC; Combination Product · Drug
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Colorectal Cancer
Interventions: Panitumumab and bortezomib; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 23
States / cities: Bellflower, California • Fullerton, California • La Jolla, California + 19 more

Conditions: Non-small Cell Lung Cancer
Interventions: Erlotinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 8
States / cities: Stanford, California • Boston, Massachusetts • Peabody, Massachusetts + 3 more

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Fulvestrant, Capivasertib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 818 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • Orange, California • San Francisco, California + 19 more

Conditions: Lung Cancer
Interventions: Itacitinib, Osimertinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 23
States / cities: La Jolla, California • San Francisco, California • Whittier, California + 19 more

Conditions: EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Panitumumab, Trametinib; Other · Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more

Conditions: Glioblastoma
Interventions: ONC201; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-321; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more

Conditions: Non-small Cell Lung Cancer, EGFR Mutations
Interventions: BIBW 2992; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR
Interventions: EPI-326; Drug
Lead sponsor: EpiBiologics; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Los Angeles, California • East Brunswick, New Jersey • Lake Success, New York + 3 more

Conditions: Metastatic Colorectal Cancer
Interventions: Cetuximab, Ulixertinib, Encorafenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Renal Function
Interventions: No Intervention; Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 5,132,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Advanced Breast Cancer
Interventions: PD-0332991 and T-DM1; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: INC280 single agent, erlotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Detroit, Michigan + 2 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Not listed
Lead sponsor: Exosome Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Hollywood, Florida • New Orleans, Louisiana

Conditions: Breast Cancer Metastatic
Interventions: Zenocutuzumab, Trastuzumab, Vinorelbine, Endocrine therapy; Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Kansas City, Kansas • Nashville, Tennessee

Search by objective public record fields.

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Understanding Mechanisms of Acquired Resistance to BIBW2992

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.